Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Development and Validation of a Noninvasive Risk Score Model for Liver Cirrhosis in At-Risk Alcohol Drinkers Without HBV/HCV Infection
Cancer Prevention Research
November 2022
Liu Y.
Open Access
Risk of Liver Cirrhosis in HBV/HCV-Infected Individuals with First-Degree Relatives Who Have Liver Cancer: Development and Validation of a Simple Model
Cancer Prevention Research
February 2022
Liu Y.
Open Access
Ferritin and liver fibrosis among patients with chronic hepatitis C virus infection
Journal of Trace Elements in Medicine and Biology
September 2020
Martín-González C.
Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: A systematic review
Clinical Chemistry and Laboratory Medicine
1 April 2019
Haghgoo S.M.
Open Access
Severe Vitamin D deficiency increases mortality among patients with liver cirrhosis regardless of the presence of HCC
In Vivo
January-February 2019
Buonomo A.R.
Open Access
Investigational direct-acting antivirals in hepatitis C treatment: The latest drugs in clinical development
Expert Opinion on Investigational Drugs
3 May 2016
Gentile I.
New direct-acting antivirals in hepatitis C therapy: A review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir
Expert Review of Clinical Pharmacology
1 February 2016
McConachie S.M.
An UPLC-MS/MS method for the quantitation of ledipasvir in rat plasma: Application to a pharmacokinetic study
Latin American Journal of Pharmacy
2016
Zhang K.
The discovery of sofosbuvir: A revolution for therapy of chronic hepatitis C
Expert Opinion on Drug Discovery
2 December 2015
Gentile I.
Asunaprevir for hepatitis C: A safety evaluation
Expert Opinion on Drug Safety
3 October 2015
Gentile I.
Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis
Expert Opinion on Investigational Drugs
2 September 2015
Jaroszewicz J.
Beclabuvir for the treatment of hepatitis C
Expert Opinion on Investigational Drugs
1 August 2015
Gentile I.
GS-9669: A novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection
Expert Review of Anti Infective Therapy
1 October 2014
Gentile I.
Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C
Plos One
18 June 2014
Coppola N.
Open Access
MK-5172: A second-generation protease inhibitor for the treatment of hepatitis C virus infection
Expert Opinion on Investigational Drugs
May 2014
Gentile I.
Efficacy and safety of sofosbuvir in the treatment of chronic hepatitis C: The dawn of a new era
Reviews on Recent Clinical Trials
2014
Gentile I.
Noninvasive scoring algorithm to identify significant liver fibrosis among treatment-naive chronic hepatitis C patients
European Journal of Gastroenterology and Hepatology
2014
Koller T.
Interferon-free therapies for chronic hepatitis C: Toward a hepatitis C virus-free world?
Expert Review of Anti Infective Therapy
July 2014
Gentile I.
Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus
Expert Review of Anti Infective Therapy
July 2014
Gentile I.
Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection
World Journal of Gastroenterology
2014
Sagnelli E.
Open Access
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus
Expert Opinion on Investigational Drugs
September 2014
Gentile I.